Core Points - Baicheng Pharmaceutical (301096.SZ) closed at 60.30 yuan, experiencing a decline of 6.37%, currently in a state of breaking issue [1] - The company was listed on the Shenzhen Stock Exchange's ChiNext board on December 20, 2021, with an initial stock issuance of 27.0417 million shares at a price of 79.60 yuan per share [1] - On its first trading day, Baicheng Pharmaceutical reached a peak stock price of 120 yuan, marking the highest price since its listing [1] Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 2.153 billion yuan, with a net amount of 1.863 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 1.213 billion yuan [1] - According to the prospectus disclosed on December 15, 2021, the company intended to raise 651 million yuan, all allocated for the headquarters and R&D center project in Hangzhou [1] Issuance Costs - The total issuance costs for the IPO amounted to 289 million yuan, with underwriting and sponsorship fees accounting for 262 million yuan [1]
百诚医药跌6.37% 2021年上市即巅峰超募12亿